Physician profile
Earl Glen Robbins
NPI 1811974298
$6,605.57
in general payments reported to CMS, 2019-2025
47 companies · $1,058 in 2025
The $1,058 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $668 · 2021: $605 · 2022: $1,155 · 2023: $1,635 · 2024: $915 · 2025: $1,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,569 · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,568.91 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,841.69 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $825.20 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Qol Medical, LLC | $661.96 | 2019-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $508.70 | 2019-2025 | Tremfya, Stelara, Remicade |
| Janssen Scientific Affairs, LLC | $316.34 | 2021-2023 | Stelara |
| Pfizer INC. | $270.72 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.86 | 2019-2024 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $151.30 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $143.19 | 2020-2025 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $137.85 | 2019-2024 | Linzess |
| Evoke Pharma, INC. | $123.19 | 2021-2025 | Gimoti |
| Genzyme Corporation | $107.90 | 2022-2025 | |
| Nestle Healthcare Nutrition INC. | $107.17 | 2022-2023 | |
| Ardelyx, INC. | $102.27 | 2022-2025 | Ibsrela |
| Gilead Sciences, INC. | $75.74 | 2023-2025 |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $67.42 | 2024-2025 | Omvoh |
| Redhill Biopharma INC. | $59.30 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Celgene Corporation | $57.79 | 2021-2023 | Zeposia |
| Madrigal Pharmaceuticals | $56.23 | 2024-2025 | Rezdiffra |
| Axonics, INC. | $56.02 | 2022-2023 | Axonics |
| Aimmune Therapeutics, INC. | $55.86 | 2024-2025 | Zenpep |
| Regeneron Healthcare Solutions, INC. | $46.95 | 2022-2024 | Dupixent |
| Amgen INC. | $45.86 | 2022-2023 | Amjevita |
| Ferring Pharmaceuticals INC. | $42.32 | 2021-2023 | Rebyota |
| Merck Sharp & Dohme LLC | $41.00 | 2022-2024 | Dificid |
| Ucb, INC. | $37.87 | 2019-2020 | |
| Vivus LLC | $31.27 | 2022-2023 | Pancreaze |
| Shield Therapeutics INC | $29.80 | 2024 | |
| Braintree Laboratories, INC. | $29.55 | 2022-2024 | Suflave |
| Novo Nordisk INC | $28.70 | 2024-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $27.87 | 2019 | |
| Shionogi INC | $27.32 | 2019 | |
| Alfasigma USA, INC. | $25.07 | 2021 | |
| Allergan, INC. | $24.93 | 2019 | |
| Sandoz INC. | $18.76 | 2023 | Hyrimoz |
| Albireo Pharma, INC. | $18.50 | 2024 | Bylvay |
| Pentax of America, INC. | $18.25 | 2022 | |
| Bioventus LLC | $17.01 | 2025 | Exogen Ultrasound Bone Healing System |
| Pharmacosmos Therapeutics INC. | $16.95 | 2021 | |
| Echosens North America, INC. | $16.88 | 2024 | Fibroscan |
| Medtronic USA, INC. | $14.86 | 2019 | |
| Olympus America INC. | $14.38 | 2025 | Evis Exera III Colonovideoscope |
| Boston Scientific Corporation | $13.98 | 2023 | Resolution 360 Clip |
| Daiichi Sankyo INC. | $12.50 | 2019 | |
| Dova Pharmaceuticals | $11.60 | 2019 | |
| Organon LLC | $11.40 | 2024 | |
| Ambu INC. | $10.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Earl Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.